Network Version
GW 501516 Data Sheet
| Product Name: | GW 501516 |
 |
|---|---|---|
| CAS No.: | 317318-70-0 | |
| Cat. No.: | HY-10838 | |
| MWt: | 453.5 | |
| Formula: | C21H18F3NO3S2 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 100 mg/mL (220.51 mM) | |
| Mechanisms: | Target: Cancer Metabolic Disease | |
| Biological Activity: | ||
| GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM[1]. IC50 & Target: EC50: 1.1 nM (PPARδ)[1] In Vitro: GW 501516 is shown to be the most potent and selective PPARδ agonists known with an EC50 of 1.1 nM against PPARδ and 1000-fold selectivity over the other human subtypes, PPARα and-γ[1]. GW 501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells. GW 501516 inhibits palmitate- and TNFα-induced increases in MCP-1 mRNA expression in a dose-dependent manner[3]. In Vivo: GW 501516 causes impaired bone formation, leading to decreased BMD and deterioration of bone properties in OVX rats[2]. GW 501516 attenuates interstitial inflammation and proximal tubular cell damage in a protein-overload mouse nephropathy model[3]. GW 501516 treatment enhances running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice[4]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com